A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 11 Sep 2017 According to an Oncoceutics media release, this trial was awarded a Fast Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) totaling $1.7 million.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 New trial record